Articles from Lungpacer Medical USA Inc.

Data presented at the American Transplant Congress 2026 reports transvenous phrenic nerve stimulation reduced lung collapse and significantly increased availability of lungs that meet transplant criteria versus contemporary historical controls

Veteran medical device executive joins to help accelerate commercialization of FDA-approved AeroPace® and development of next-generation AeroNova® Systems

AeroPace temporary transvenous diaphragm neurostimulation system now available to help critically ill patients breathe independently faster

STARI will investigate continual diaphragm neurostimulation to improve lung, diaphragm, cardiac and brain function at the earliest stages of mechanical ventilation

Exton, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical Inc., a medical technology company focused on neurostimulation therapies for critically ill patients, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-on Payment (NTAP) status for the AeroPace® System under the Fiscal Year 2026 Inpatient Prospective Payment System (IPPS) Final Rule, effective October 1, 2025.

EXTON, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- This spring, Lungpacer Medical clinical experts and device innovators will be featured presenters at top industry events. Speakers will demonstrate how novel interventional therapies can free critically ill patients from mechanical ventilation and may help improve lung, heart, and brain health in ventilated patients.

International multi-center trial demonstrates AeroPace strengthens the diaphragm by 50%, weans more patients from ventilation, and reduces ventilator time by 3 days in patients difficult to wean from mechanical ventilation

Company Appoints Medical Device and Healthcare Industry Veteran with 20 Years of Experience

The investigational AeroNova® System delivers continual diaphragm neurostimulation in conjunction with mechanical ventilation and is designed to mitigate the negative effects of ventilation that cause multi-organ ventilator-induced injury.

The investigational AeroNova® System delivers continual diaphragm neurostimulation in synchrony with mechanical ventilation and is designed to reduce injurious pressures from mechanical ventilation to mitigate multi-organ ventilator-induced injury to patients on ventilation

AeroPace is a minimally invasive transvenous diaphragm strengthening neurostimulation therapy for quicker patient liberation from mechanical ventilation

AeroPace is a minimally invasive transvenous diaphragm strengthening neurostimulation therapy designed for quicker liberation from mechanical ventilation